SCHEMBL7218672

SCHEMBL7218672

Cc1ccc(C(=O)c2cccc(N)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.72
LMNA P02545 3/20 0.72
NPC1 O15118 3/20 0.72
MITF O75030 1/20 0.72
POLB P06746 1/20 0.72
ALDH1A1 P00352 3/20 0.59
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA9 Q16790 1/20 0.58
SRD5A2 P31213 1/20 0.52
MAPT P10636 5/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
ATM Q13315 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPK13 O15264 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
MAPK14 Q16539 1/20 0.49
GAA P10253 1/20 0.47
CES2 O00748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203373 0.90 PBRM1 (0.88) PBRM1LMNANPC1MITFPOLB
SCHEMBL29492473 0.90 PBRM1 (0.88) PBRM1LMNANPC1MITFPOLB
SCHEMBL9097509 0.90 PBRM1 (0.88) PBRM1LMNANPC1MITFPOLB
SCHEMBL9973084 0.87 PBRM1 (0.69) PBRM1LMNANPC1MITFPOLB
SCHEMBL29037240 0.86 PBRM1 (0.81) PBRM1LMNANPC1MITFPOLB
SCHEMBL17744847 0.86 PBRM1 (0.81) PBRM1LMNANPC1MITFPOLB
SCHEMBL127545 0.86 PBRM1 (0.81) PBRM1LMNANPC1MITFPOLB
SCHEMBL5114913 0.86 PBRM1 (0.81) PBRM1LMNANPC1MITFPOLB
SCHEMBL5832368 0.86 PBRM1 (0.81) PBRM1LMNANPC1MITFPOLB
SCHEMBL8549972 0.86 LMNA (0.73) PBRM1LMNANPC1MITFPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 US disclosed
US-6623786-B2 Method for hydrogel surface treatment NOVARTIS AG (CH) 2003-09-23 US disclosed
US-20010024697-A1 Method for hydrogel surface treatment and article formed therefrom BARON RICHARD CARLTON (US) 2001-09-27 US disclosed
EP-1023617-A1 METHOD FOR HYDROGEL SURFACE TREATMENT AND ARTICLE FORMED THEREFROM Novartis AG (CH) 2000-08-02 EP disclosed
WO-1999015917-A1 METHOD FOR HYDROGEL SURFACE TREATMENT AND ARTICLE FORMED THEREFROM NOVARTIS AG (CH) 1999-04-01 WO disclosed
US-RE29032-E ANTIINFLAMMATORY AGENTS RIKER LABORATORIES, INC. (US) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 PBRM1 4429/4885LMNA 1126/4885NPC1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.